All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
On 20th August 2017, in a Bed-to-Bench-Letter to Experimental Dermatology, Shikha Rao from the Emory University School of Medicine Atlanta Veterans Administration Medical Center, Atlanta, GA, USA, et al. presented a case report of a female patient, 84 years of age, with primary cutaneous Diffuse Large B-Cell Lymphoma (DLBCL), leg type.
The authors hypothesized that gentian violet results in signaling changes in DLBCL cells allowing immune clearance to take place. They propose that gentian violet downregulates NADPH oxidase causing subsequent downregulation of NF-kB and Sox2, enhancing antigen presentation of tumor antigens on the cell surface. The authors concluded that gentian violet, as well as similar NADPH-oxidase inhibitors, given systemically warrants further assessment in human Lymphoma in pre-clinical trials.
In this case report, a patient of Primary Cutaneous Diffuse B-cell lymphoma, leg type was treated with intralesional gentian violet as she was judged to be too medically fragile for conventional chemotherapy due to advanced age and multiple serious comorbidities. Gentian violet (Crystal violet/ hexamethyl pararosaniline) is a triphenylmethane dye. It has been shown to have an inhibitory effect on NADPH oxidase, an enzyme family which is found in abundance in reactive oxygen driven tumors such as melanoma and lymphoma. We hypothesize that intralesional gentian violet treatment caused signaling changes in the lymphoma which allowed for immune clearance of the lymphoma. Complete resolution of the patient's lesion was noted on a follow up visit.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox